Listed by the USPTO as DICKENS, AMELIA NICOLE
Tech Center 1600 • Art Units: 1644 1645 1671
This examiner grants 48% of resolved cases
DICKENS, AMELIA NICOLE is assigned to art unit 1644 within tech center 1600. The profile includes 128 resolved cases, an allowance rate of 47.7%, and a median of 1277 days to allowance. Interviews are associated with a 22.5% lift in the allowance measure.
Listed company matters include Intervet Inc., The Regents of the University of California, and CJ CheilJedang Corporation. Listed firms are Morgan, Lewis & Bockius LLP (WA), SUGHRUE MION, PLLC, and ARENTFOX SCHIFF LLP. Practitioners can use the combination of recorded timing and interview response to structure prosecution plans, while the case volume calls for care in treating the profile as a prediction for any individual application.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18016432 | RECOMBINANT MICROORGANISMS | Non-Final OA | The Regents of the University of California |
| 18852236 | COMPOSITION CONTAINING BACILLUS AMYLOLIQUEFACIENS STRAIN FOR ENHANCING PLANT DISEASE RESISTANCE AND USE THEREOF | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 19150973 | METHODS FOR PRODUCING HIGH-LEVEL SQUALENE | Non-Final OA | Massachusetts Institute of Technology |
| 18574816 | BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF | Non-Final OA | Société des Produits Nestlé S.A. |
| 18690364 | METHOD AND COMPOSITION FOR REDUCING OR PREVENTING FIRE BLIGHT DISEASE IN A POME FRUIT TREE | Final Rejection | The Penn State Research Foundation |
| 18665951 | PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18466984 | METHOD FOR PRODUCING FOREIGN PROTEIN USING E. COLI | Non-Final OA | KANEKA CORPORATION |
| 19161632 | Use of O-Antigens for Treating Bacterial Infections | Non-Final OA | Agency for Science, Technology and Research |
| 18292542 | VACCINE COMPOSITIONS COMPRISING BRUCELLA STRAINS AND METHODS THEREOF | Final Rejection | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18286005 | ENCAPSULATED MICROBIAL COMPOSITIONS AND METHODS OF MAKING THE SAME | Final Rejection | Monsanto Technology LLC |
| 17788224 | PROCESS TO IDENTIFY CONSORTIA OF PROBIOTIC STRAINS SUITABLE FOR GLUTEN DEGRADATION | Final Rejection | Evonik Operations GmbH |
| 17335578 | METHODS FOR ASSESSING EFFICACY OF A DRUG IN VIVO BY MONITORING ADME PROTEINS IN EXTRACELLULAR VESICLES | Final Rejection | Purdue Research Foundation |
| 18167664 | Microbially Induced Inflammation Produces Changes in Distinct Healthy Tissues in Human Oral Cavity | Final Rejection | Colgate-Palmolive Company |
| 18261226 | COMPOSITION FOR DECOMPOSITION OF TRYPSIN OR TMPRSS2 | Non-Final OA | Keio University |
| 18467134 | COMPLEX OR SALT THEREOF, AND METHOD FOR PRODUCING THE SAME | Non-Final OA | Ajinomoto Co., Inc. |
| 17775425 | A NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | Non-Final OA | Intervet Inc. |
| 17775428 | NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | Non-Final OA | Intervet Inc. |
| 18824806 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18287081 | GROWTH PROMOTER FOR LACTIC ACID COCCI | Final Rejection | KIRIN HOLDINGS KABUSHIKI KAISHA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy47.7% of resolved applications examined by Amelia Nicole Dickens were allowed (128 resolved cases), compared with 35.8% across Art Unit 1644 over the last five years.
This examiner's interview lift is +22.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amelia Nicole Dickens took 1,277 days on average from filing to allowance.
Amelia Nicole Dickens examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).